Avaxia Biologics generates compelling pre-clinical data in pet models of IBD Avaxia Biologics, Inc., a privately-held biotech organization developing a forward thinking platform technology to provide orally-energetic antibodies to the gastrointestinal system, announced today that it offers generated compelling pre-clinical data in pet types of inflammatory bowel disease . Avaxia’s orally administered anti-TNF product AVX-470 significantly reduced disease intensity in three different pet models and showed excellent efficacy to an oral steroid medication in a comparative check of disease remission check .
Avila, sanofi-aventis enter global alliance to find targeted covalent medicines for treatment of cancers Avila Therapeutics, Inc. Announced today that it provides signed an internationally strategic alliance with sanofi-aventis to find targeted covalent medicines for the treating cancers. Beneath the alliance contract sanofi-aventis obtains an internationally exclusive license to build up and commercialize the substances caused by the discovery collaboration.D., Senior Vice President and Mind of Oncology, sanofi-aventis. ‘We think that Avila’s approach increases our developing portfolio of study capabilities that may provide medicines which considerably improve individual outcomes.’ Within the extensive research alliance, sanofi-aventis will work as well as Avila to create targeted covalent medications directed towards six signaling proteins which are vital in tumor cells.